ESOPJul 23, 2026, 05:21 PM
Sensei Biotherapeutics Grants Performance Options with $70 Stock Hurdle
AI Summary
Sensei Biotherapeutics' Board approved one-time supplemental performance-based stock options under its 2026 Equity Incentive Plan for current employees, including CEO Anand Parikh and other executives. These options vest upon achieving a stock price hurdle of $70.00 within four years, subject to continued employment. The exercise price is the closing price on the grant date, and options are forfeited if the hurdle is not met or service terminates.
Key Highlights
- Board approved one-time performance-based stock options for employees.
- CEO Anand Parikh granted 398,018 performance options.
- General Counsel Christopher Gerry granted 84,766 performance options.
- SVP Finance Josiah Craver granted 30,824 performance options.
- Options vest if stock price reaches $70.00 within 4 years.
- Vesting requires continued service with the company.
- Exercise price equals the closing price on the grant date.
- Options forfeit if stock price hurdle not met or service terminates.
Price Impact
More from SNSE